Metformin’s Therapeutic Efficacy in the Treatment of Diabetes Does Not Involve Inhibition of Mitochondrial Glycerol Phosphate Dehydrogenase

• Published in: Diabetes (New York, N.Y.) Vol. 70; no. 7; pp. 1575 - 1580
• Main Authors: MacDonald, Michael J., Ansari, Israr-ul H., Longacre, Melissa J., Stoker, Scott W.
• Format: Journal Article
• Language: English
• Published: New York American Diabetes Association 01.07.2021
• Subjects: Beta cells; Dehydrogenases; Diabetes; Diabetes mellitus (non-insulin dependent); Enzymes; Gluconeogenesis; Glycerol; Hepatocytes; Insulin; Insulin secretion; Liver; Metformin; Mitochondria; Pancreas; Side effects
• ISSN: 0012-1797; 1939-327X
• DOI: 10.2337/db20-1143

Mitochondrial glycerol phosphate dehydrogenase (mGPD) is the rate-limiting enzyme of the glycerol phosphate redox shuttle. It was recently claimed that metformin, a first-line drug used for the treatment of type 2 diabetes, inhibits liver mGPD 30–50%, suppressing gluconeogenesis through a redox mechanism. Various factors cast doubt on this idea. Total-body knockout of mGPD in mice has adverse effects in several tissues where the mGPD level is high but has little or no effect in liver, where the mGPD level is the lowest of 10 tissues. Metformin has beneficial effects in humans in tissues with high levels of mGPD, such as pancreatic β-cells, where the mGPD level is much higher than that in liver. Insulin secretion in mGPD knockout mouse β-cells is normal because, like liver, β-cells possess the malate aspartate redox shuttle whose redox action is redundant to the glycerol phosphate shuttle. For these and other reasons, we used four different enzyme assays to reassess whether metformin inhibited mGPD. Metformin did not inhibit mGPD in homogenates or mitochondria from insulin cells or liver cells. If metformin actually inhibited mGPD, adverse effects in tissues where the level of mGPD is much higher than that in the liver could prevent the use of metformin as a diabetes medicine.